Clinical trial · Observational
Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma
NCT01557127CI-TRIAL-00026665NEXSTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sorafenib (Nexavar, BAY43-9006) | Drug | Sorafenib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Group 1
- interventionNames
- Drug: Sorafenib (Nexavar, BAY43-9006)
Primary outcomes (1)
- measure
- Percentage of patients in whom the actual dose of sorafenib equaled the planned dose
- timeFrame
- 12 months
Secondary outcomes (1)
- measure
- Overall tolerability of treatment as measured by rate of adverse events
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>/= 18 years * Diagnosis of renal cell carcinoma * Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or disqualified from therapy with IFN/IL-2 * Patients in whom the oncologist has decide to start therapy with sorafenib. Exclusion Criteria: * Synonymous with contraindications to Nexavar.
References
Publications (0)
Data not yet available
No reference posted for this study.